Efficacy of local therapy for oligoprogressive disease after programmed cell death 1 blockade in advanced non‐small cell lung cancer

Immune checkpoint inhibitors (ICIs) have dramatically changed the strategy used to treat patients with non‐small‐cell lung cancer (NSCLC); however, the vast majority of patients eventually develop progressive disease (PD) and acquire resistance to ICIs. Some patients experience oligoprogressive dise...

Descripción completa

Detalles Bibliográficos
Autores principales: Kagawa, Yusuke, Furuta, Hiromi, Uemura, Takehiro, Watanabe, Naohiro, Shimizu, Junichi, Horio, Yoshitsugu, Kuroda, Hiroaki, Inaba, Yoshitaka, Kodaira, Takeshi, Masago, Katsuhiro, Fujita, Shiro, Niimi, Akio, Hida, Toyoaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7734009/
https://www.ncbi.nlm.nih.gov/pubmed/32770608
http://dx.doi.org/10.1111/cas.14605

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7734009/
https://www.ncbi.nlm.nih.gov/pubmed/32770608
http://dx.doi.org/10.1111/cas.14605

Ejemplares similares